Building the operating systems behind better medicines.
Founder, CEO & CTO of NEUVIOR. Product architect of PHARMORIS. Glasgow-born and British-Indian, focused on turning evidence into accountable action.
Current focus — NEUVIOR and PHARMORIS · Long-term thesis — intelligence, advanced manufacturing and extreme-environment science
Varun’s current work is concentrated in one pharmaceutical operating thesis. Present activity and long-term ambition are deliberately kept separate.
NEUVIOR
Varun founded NEUVIOR to connect medicines evidence, human decision-making and accountable execution. The company’s public record is intentionally bounded by source and status.
Operating company · Incorporated in Scotland, 2025
PHARMORIS
PHARMORIS is under controlled, non-production development as a staff-facing system intended to help teams move from fragmented evidence to reviewable action.
Controlled development · Not presented as deployed or clinically validated
Recorded Innovate UK grant offers across two closed project records.
UKRI recordsPHARMORIS and VIONIX ZERO in the UKRI Gateway to Research.
Project registerNEUVIOR’s 2025–26 NHS DSP Toolkit submission; not an NHS endorsement.
DSP Toolkit recordVerified 02 August 2026 · Definitions and limitations remain visible.
“My dad’s corner shop taught me that systems only matter when they work for the person standing in front of you.”
Glasgow-born and British-Indian, Varun began with the practical logic of family business: listen closely, keep promises visible and solve the problem in front of you. He now applies that instinct to medicines, technology and the institutions around them.
Public voice — neurodivergent entrepreneurship · medicines access · accountable innovation
Read the full biography
The ambition is expansive. The operating focus is not.
Operating company and controlled product development.
Discovery and predevelopment; no customer, facility or partnership implied.
Long-horizon research and venture concepts spanning extreme environments, luxury and space.
Stage labels describe present evidence, not future certainty.
Editorial coverage, founder commentary and project reporting are labelled by type. Publication is a record; it is not proof of deployment or endorsement.